{
  "abstract": "Nirsevimab, a long-acting monoclonal antibody, was introduced last season (2023–2024) in some countries with the aim of reducing the burden of disease caused by respiratory syncytial virus (RSV) in infants.",
  "authors": [
    {
      "affiliations": [
        "Primary Care Services Information System (SISAP), Institut Català de la Salut, Barcelona, Catalunya, Spain",
        "SISAP Research Group (GR-SISAP), Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAP Jordi Gol), Barcelona, Spain"
      ],
      "name": "Ermengol Coma"
    },
    {
      "affiliations": [
        "Public Health Secretariat, Department of Health, Government of Catalonia, Barcelona, Catalonia, Spain"
      ],
      "name": "Montserrat Martinez-Marcos"
    },
    {
      "affiliations": [
        "Primary Care Services Information System (SISAP), Institut Català de la Salut, Barcelona, Catalunya, Spain",
        "SISAP Research Group (GR-SISAP), Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAP Jordi Gol), Barcelona, Spain"
      ],
      "name": "Eduardo Hermosilla"
    },
    {
      "affiliations": [
        "Sub-Directorate General of Surveillance and Response to Public Health Emergencies, Public Health Secretariat, Department of Health, Government of Catalonia, Barcelona, Spain"
      ],
      "name": "Jacobo Mendioroz"
    },
    {
      "affiliations": [
        "Primary Care Services Information System (SISAP), Institut Català de la Salut, Barcelona, Catalunya, Spain"
      ],
      "name": "Anna Reñé"
    },
    {
      "affiliations": [
        "Primary Care Services Information System (SISAP), Institut Català de la Salut, Barcelona, Catalunya, Spain",
        "SISAP Research Group (GR-SISAP), Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAP Jordi Gol), Barcelona, Spain"
      ],
      "name": "Francesc Fina Avilés"
    },
    {
      "affiliations": [
        "Department of Physics, Universitat Politècnica de Catalunya (UPC-BarcelonaTech), Barcelona, Spain"
      ],
      "name": "Aida Perramon"
    },
    {
      "affiliations": [
        "Department of Physics, Universitat Politècnica de Catalunya (UPC-BarcelonaTech), Barcelona, Spain"
      ],
      "name": "Clara Prats"
    },
    {
      "affiliations": [
        "Respiratory Virus Unit, Microbiology Department, Hospital Vall d’Hebron, Barcelona, Catalonia, Spain"
      ],
      "name": "Andrés Antón"
    },
    {
      "affiliations": [
        "Department of Paediatrics, Serveis de Salut Integrats del Baix Empordà, Palamós, Spaiin"
      ],
      "name": "Antoni Soriano-Arandes"
    },
    {
      "affiliations": [
        "Public Health Secretariat, Department of Health, Government of Catalonia, Barcelona, Catalonia, Spain"
      ],
      "name": "Carmen Cabezas"
    }
  ],
  "title": "Effectiveness of nirsevimab against RSV-related outcomes: findings of the 2024–2025 campaign in Catalonia align with previous analysis",
  "uid": "886e3737-6983-5597-8a17-373896ac8e61"
}